Literature DB >> 31604893

Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies.

Ismet Sarikaya1, Ahmed N Albatineh2, Ali Sarikaya3.   

Abstract

SUV normalized by total body weight is affected by the amount of body fat. The SUV of normal tissues and lesions is higher (overestimated) in obese patients than in patients with a normal body mass index (BMI). SUL (SUV normalized by lean body mass [LBM]) is recommended for more accurate SUV results. Given the importance of a quantitative PET parameter, particularly when comparing PET studies, we aimed to revisit the effect of obesity on SUV, measuring SUL in normal-BMI patients and obese patients and testing the effect of the amount of LBM.
Methods: 18F-FDG whole-body images of adult patients were analyzed retrospectively. We measured both SUVmax and SUVmean in the blood pool and liver of patients with a normal BMI (18.5-24.9) and a high BMI (≥30) (obese). In all patients, we calculated LBM via an equation using patient height and weight and corrected all SUVs to SULs. Mean (±SD) SUVs and SULs were compared under various circumstances. Scatterplots were generated for weight and SUV-SUL differences.
Results: SUVmean in the liver and blood pool was significantly higher in obese patients (30 patients) than in patients with a normal BMI (20 patients) (4.1 ± 0.7 and 3.0 ± 0.5, respectively, in liver, vs. 3.2 ± 0.6 and 2.4 ± 0.4, respectively, in blood pool; P < 0.001). SULmean was significantly lower in both liver and blood pool in all patients, being approximately 75% of SUVmean in patients with a normal BMI and 55% of SUVmean in obese patients (P < 0.001). SULmean in the liver and blood pool did not significantly differ between obese patients and normal-BMI patients (P > 0.05). The SUV-SUL difference was significantly higher in obese patients than in patients with a normal BMI (P < 0.001). These statistical results were the same when SUVmax and SULmax were compared.
Conclusion: SUV overestimates metabolic activity in all patients, and this overestimation is more significant in obese patients than in patients with a normal BMI. SUL is not affected by body weight or the amount of LBM.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET; SUL; SUV; lean body mass; weight

Mesh:

Substances:

Year:  2019        PMID: 31604893     DOI: 10.2967/jnmt.119.233353

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  5 in total

1.  Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?

Authors:  Gundula Rendl; Gregor Schweighofer-Zwink; Stefan Sorko; Hans-Jürgen Gallowitsch; Wolfgang Hitzl; Diana Reisinger; Christian Pirich
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

2.  SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans.

Authors:  Bradley J Beattie; Tim J Akhurst; Finn Augensen; John L Humm
Journal:  PLoS One       Date:  2022-04-21       Impact factor: 3.752

3.  Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET-A Significant Improvement Over Prediction Equations.

Authors:  Terence A Riauka; Vickie E Baracos; Rebecca Reif; Freimut D Juengling; Don M Robinson; Marguerite Wieler; Alexander J B McEwan
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

4.  Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained from 18F-FDG PET/CT.

Authors:  Sungmin Kang; Joo Dong Kim; Dong Lak Choi; Byungwook Choi
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

5.  Quantitative Analysis of SPECT-CT Data in Metastatic Breast Cancer Patients-The Clinical Significance.

Authors:  Mirela Gherghe; Mario-Demian Mutuleanu; Adina Elena Stanciu; Ionela Irimescu; Alexandra Lazar; Xenia Bacinschi; Rodica Maricela Anghel
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.